JP2021525729A5 - - Google Patents

Info

Publication number
JP2021525729A5
JP2021525729A5 JP2020566655A JP2020566655A JP2021525729A5 JP 2021525729 A5 JP2021525729 A5 JP 2021525729A5 JP 2020566655 A JP2020566655 A JP 2020566655A JP 2020566655 A JP2020566655 A JP 2020566655A JP 2021525729 A5 JP2021525729 A5 JP 2021525729A5
Authority
JP
Japan
Prior art keywords
composition
sepiapterin
subject
effective amount
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525729A (ja
JP7502197B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034523 external-priority patent/WO2019232130A1/en
Publication of JP2021525729A publication Critical patent/JP2021525729A/ja
Publication of JP2021525729A5 publication Critical patent/JP2021525729A5/ja
Priority to JP2024015822A priority Critical patent/JP7841005B2/ja
Application granted granted Critical
Publication of JP7502197B2 publication Critical patent/JP7502197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566655A 2018-05-30 2019-05-30 セピアプテリン血漿曝露を増加させるための方法 Active JP7502197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015822A JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US62/677,943 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US62/771,398 2018-11-26
US201962822376P 2019-03-22 2019-03-22
US62/822,376 2019-03-22
GC2019-37663 2019-05-28
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015822A Division JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Publications (3)

Publication Number Publication Date
JP2021525729A JP2021525729A (ja) 2021-09-27
JP2021525729A5 true JP2021525729A5 (https=) 2022-06-03
JP7502197B2 JP7502197B2 (ja) 2024-06-18

Family

ID=68699037

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566655A Active JP7502197B2 (ja) 2018-05-30 2019-05-30 セピアプテリン血漿曝露を増加させるための方法
JP2024015822A Active JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024015822A Active JP7841005B2 (ja) 2018-05-30 2024-02-05 セピアプテリン血漿曝露を増加させるための方法

Country Status (20)

Country Link
US (3) US11617752B2 (https=)
EP (2) EP4454704A3 (https=)
JP (2) JP7502197B2 (https=)
CN (1) CN112703002A (https=)
AU (2) AU2019277382B2 (https=)
CA (1) CA3102106A1 (https=)
DK (1) DK3801536T3 (https=)
ES (1) ES2986920T3 (https=)
FI (1) FI3801536T3 (https=)
HR (1) HRP20241213T1 (https=)
HU (1) HUE068589T2 (https=)
LT (1) LT3801536T (https=)
MD (1) MD3801536T2 (https=)
MX (2) MX2020012979A (https=)
PL (1) PL3801536T3 (https=)
PT (1) PT3801536T (https=)
RS (1) RS65874B1 (https=)
SI (1) SI3801536T1 (https=)
SM (1) SMT202400430T1 (https=)
WO (1) WO2019232130A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
EP4093405A1 (en) * 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
IL305037A (en) * 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
WO2022173823A1 (en) * 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー. ランドリ,ドナルド 抗体触媒反応の調節による有機化合物の検出
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
EP1687308B1 (en) 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
BRPI0609421B1 (pt) 2005-04-28 2021-06-01 Shiratori Pharmaceutical Co., Ltd. Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
EP2562176B1 (en) * 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN104736539B (zh) 2012-05-07 2017-09-01 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法
EP3213062B1 (en) * 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
WO2019102315A1 (en) * 2017-11-23 2019-05-31 Semiconductor Energy Laboratory Co., Ltd. Display device and electronic device
EP3801534B1 (en) * 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Similar Documents

Publication Publication Date Title
JP2021525729A5 (https=)
JP2024063143A5 (https=)
JP2024069192A5 (https=)
FI3801536T3 (fi) Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
TW200838545A (en) Therapeutic agent for painful disease
RU2010121827A (ru) Композиции для лечения болезни паркинсона
JP2015519404A5 (https=)
JP2013544887A5 (https=)
JP2021525746A5 (https=)
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
FI3801534T3 (fi) Fenyyliketonurian hoito sepiapteriinilla
US20260053808A1 (en) Novel uses
RU2009119258A (ru) Способ лечения воспалительных заболеваний кишечника
JP2018531273A5 (https=)
US20030195255A1 (en) Method for treating hepatic encephalopathies
KR20180034442A (ko) 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
JP2022514537A5 (https=)
JP2023553253A5 (https=)
JP2022525202A (ja) 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と1日あたりの投薬量
JP2016505050A5 (https=)
JP2023541007A5 (https=)
JP6704252B2 (ja) 位置特異的非対称重水素富化カテコールアミン誘導体および前記化合物を含有する医薬
JP2019507786A5 (https=)
JP2020531543A (ja) アマンタジン組成物、その調製、および使用方法
JP2019531286A5 (https=)